文献速递银屑病与炎症性皮肤病

早期系统性炎症蛋白定量可预测托法替布与依那西普长期治疗反应

Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept.
PubMed 文献 · J Invest Dermatol · 2019-11-06

该研究对银屑病患者基线和治疗4周后的血液中92种炎症蛋白和65种心血管疾病蛋白进行纵向检测,利用机器学习(bagging与集成方法)构建预测模型。模型可准确预测托法替布治疗12周临床终点(验证集auROC=78%)和依那西普治疗12周临床终点(验证集auROC=71%),并发现包含IL-17A和IL-17C等银屑病标志物的稳健预测蛋白特征。

要点

  • 血蛋白数据可预测托法替布12周疗效(auROC=78%)和依那西普12周疗效(auROC=71%)。
  • 预测蛋白特征包含IL-17A和IL-17C等已知银屑病标志物。
  • 多数血液分类器性能不及基于PASI评分的简单模型,但未来可扩展蛋白种类提升性能。

核心结论

  • 基于血液炎症和心血管蛋白的机器学习模型能准确预测银屑病患者对托法替布或依那西普的12周临床反应。

研究设计与样本

  • 纵向检测银屑病患者基线和治疗4周后血液中92种炎症蛋白和65种心血管疾病蛋白,使用bagging和集成等机器学习技术构建预测模型,并在验证数据集评估。

主要发现

  • 托法替布治疗12周临床终点的预测模型在验证集auROC=78%。
  • 依那西普治疗12周临床终点的预测模型在验证集auROC=71%。
  • 预测蛋白特征包括IL-17A和IL-17C等已知银屑病标志物。
  • 多数血液分类器性能不及基于PASI评分的简单模型。

关键数值与推荐

  • 托法替布预测模型验证集auROC=78%。
  • 依那西普预测模型验证集auROC=71%。

临床怎么用

  • 血蛋白数据有望作为 cheaper、less invasive 的预测平台,辅助银屑病治疗反应预测。
  • 当前模型性能多数不及PASI评分模型,临床使用需谨慎。

局限性

  • 多数血液分类器性能不及基于PASI评分的简单模型。
  • 未来需测量更广泛蛋白种类以提升性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The application of machine learning to longitudinal gene-expression profiles has demonstrated potential to decrease the assessment gap, between biochemical determination and clinical manifestation, of a patient's response to treatment. Although psoriasis is a proven testing ground for treatment-response prediction using transcriptomic data from clinically accessible skin biopsies, these biopsies are expensive, invasive, and challenging to obtain from certain body areas. Response prediction from blood biochemical measurements could be a cheaper, less invasive predictive platform. Longitudinal profiles for 92 inflammatory and 65 cardiovascular disease proteins were measured from the blood of psoriasis patients at baseline, and 4-weeks, following tofacitinib (janus kinase-signal transducer and activator of transcription-inhibitor) or etanercept (tumor necrosis factor-inhibitor) treatment, and predictive models were developed by applying machine-learning techniques such as bagging and ensembles. This data driven approach developed predictive models able to accurately predict the 12-week clinical endpoint for psoriasis following tofacitinib (area under the receiver operating characteristic curve [auROC] = 78%), or etanercept (auROC = 71%) treatment in a validation dataset, revealing a robust predictive protein signature including well-established psoriasis markers such as IL-17A and IL-17C, highlighting potential for biologically meaningful and clinically useful response predictions using blood protein data. Although most blood classifiers were outperformed by simple models trained using Psoriasis Area Severity Index scores, performance might be enhanced in future studies by measuring a wider variety of proteins.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Tomalin LE, Kim J, Correa da Rosa J, et al. Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept. J Invest Dermatol. 2019. PMID: 31705874. doi:10.1016/j.jid.2019.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。